Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

For me this publication speaks about using nanoparticles

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
frenchbroad Member Profile
 
Followed By 15
Posts 1,327
Boards Moderated 0
Alias Born 08/02/19
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2021 1:45:15 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close InvestorsHub NewsWire - 11/5/2021 10:20:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/14/2021 5:01:12 PM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CEO's Presenting on the Emerging Growth Conference 17 TODAY.  Register Now InvestorsHub NewsWire - 9/29/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
Innovation Pharma selected for a presentation on experimental COVID-19 therapy Seeking Alpha - 6/18/2021 10:31:54 AM
The Emerging Growth Conference is Today.  Register Now. InvestorsHub NewsWire - 6/9/2021 7:00:00 AM
Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial Seeking Alpha - 5/27/2021 10:29:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 8:01:45 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/3/2021 12:54:36 PM
Innovation gives update on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 4/5/2021 8:03:34 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Innovation updates on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 3/5/2021 1:07:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/22/2021 11:20:39 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/17/2021 8:01:12 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/11/2021 4:47:49 PM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
frenchbroad   Wednesday, 09/29/21 03:33:27 PM
Re: sunspotter post# 376580
Post # of 387629 
For me this publication speaks about using nanoparticles together with antibiotics to make bacteria more susceptible to destruction. If I understand well, they say a reason for drug resistance is a *efflux pump system* in the bacteria. It is maybe not correct but I imagine a wee pump in the bad bacteria that can expel or reject a drug that is supposed to kill it. *The major cause of resistance to date is the efflux system, which makes the latest generation of antibiotics ineffective without reaching the target site. If species-specific nanomaterials are used to control the activity of efflux pumps, it could revolutionize the field of medicine and make the previous generation resistant medications active once again.*

Brilacidin is a new antibiotic that demonstrated in trial it can kill drug-resistant MRSA bacteria quickly. If there is new technology that can help Brilacidin work even better I would be happy to learn more on this. And Google says that Brilacidin is mentioned in this publication.

Maybe it is nothing like Mr. KMBJN says. But if you can access this publication I would appreciate to have a look.
Thank you.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences